Canada Approves Meridian Bio's Molecular Assays for M. Pneumonia, B. Pertussis | GenomeWeb

NEW YORK (GenomeWeb) – Meridian Bioscience today announced that Health Canada has approved for marketing Meridian's molecular assays for Mycoplasma pneumonia and Bordetella pertussis on the company's illumigene platform.

The M. pneumonia test amplifies specific DNA to detect the bacterium and help patients receive appropriate treatment in a timely manner. The B. pertussis test similarly amplifies a specific DNA target to detect that bacterium. It uses nasopharyngeal swab samples and takes less than sixty minutes to report a result.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.